ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO258

Linezolid Adsorption During In Vitro Model of Hemoperfusion with Mini-Module of HA380 Cartridge

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Authors

  • Lorenzin, Anna, San Bortolo Hospital and IRRIV, Vicenza, Italy
  • de Cal, Massimo, San Bortolo Hospital and IRRIV, Vicenza, Italy
  • Ronco, Claudio, San Bortolo Hospital and IRRIV, Vicenza, Italy
  • Zanella, Monica, San Bortolo Hospital and IRRIV, Vicenza, Italy
Background

AKI due to sepsis is the result of a dysregulated host immune response to infection, with the production of inflammatory mediators and cytokines. Jafron HA380 cartridge has been specifically designed for cytokine storm in sepsis. Given the growing application of these hemoperfusion device, an unsolved problem is whether these polymers adsorb drugs, including antibiotics.
In vitro experiments were conducted to determine its adsorption capacity towards Linezolid (LZD) antibiotic.

Methods

In vitro circulation was performed using a dedicated testing platform Galileo. A customized cartridge was built assembling mini-module components scaled in dimension towards HA380 and filled with 75g of HA380 beads (25% of the regular size). Blood pump was set at 250ml/min. Saline and human blood solutions enriched with 600mg of LZD have been tested for 2hrs. Samples were collected after the first passage (FP) through the cartridge and every 5 or 10min. LZD concentrations were measured. Adsorption was assessed considering the Removal Ratio:RR(%)=100x(C0- Ct)/ C0.

Results

Experiment with saline solution was performed in duplicate. In vitro circulation confirms the affinity of beads material in binding LZD. The kinetics shows a rapid adsorption in the very first part of the experiments, after that the adsorption rate decreased due to the decrease of antibiotic available in the solution. After FP of the solution through the cartridge, a RR higher than 80% has been achieved. At the end of the experiments the adsorption reached about the 100% of RR. Blood circulation reinforced these results: the RR of FP was higher than 80%, and at the end the mass injected in the solution was almost entirely adsorbed (see table).

Conclusion

HA380 adsorbs significant amounts of LZD. Further investigation using a higher quantity of LZD is necessary to reach the saturation of the cartridge and understand the sorbent material capacity. These preliminary results highlight that there is an interaction that could affect the clinical outcome.